CRX100 drug trial for advanced cancers with or without pembrolizumab
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and be able to sign consent before any study procedures.
- Have a confirmed diagnosis of one of these cancers: triple-negative breast, colon/rectal, liver (hepatocellular carcinoma), osteosarcoma, epithelial ovarian, melanoma, non-small cell lung cancer, or stomach cancer.
- Your cancer must have come back or not responded to standard treatments (or you couldn’t tolerate them).
- Have at least one measurable tumor spot on CT or MRI with IV contrast, and be well enough to do daily activities (ECOG 0–1).
- Be able to give fresh tumor tissue (not previously irradiated), or archival tissue if a new biopsy is unsafe.
- Have adequate blood counts and organ function on screening, and have not had certain cancer treatments/immunotherapies, radiation, or investigational drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.